Fragile X Research in the News: Kaerus Bioscience’s Successful Phase 1 Trial
In exciting news for the Fragile X community, Kaerus Bioscience has announced the successful completion of its Phase 1 clinical trial for KER-0193, a novel BK channel modulator being developed to treat Fragile X syndrome (FXS). This achievement marks significant progress towards the search for effective treatments for those living with FXS.

What’s the Big News?
The Phase 1 trial demonstrated “proof of mechanism” for KER-0193, meaning that the drug works as expected at a biological level. More importantly, the trial found that KER-0193 was safe and well-tolerated by participants, which is a crucial step in the development of any new treatment.
This progress is an exciting development in the ongoing efforts to find better treatments for FXS. As researchers continue to push the boundaries of what is possible, this trial success brings us one step closer to more effective therapies for this neurodevelopmental disorder.
The National Fragile X Foundation talked to Dr. Robert Ring, CEO of Kaerus Bioscience, and he shared:
Why Does This Matter?
For families living with Fragile X, new treatment options are a hopeful sign that progress is being made. With no cure currently available, every step forward in research offers the possibility of better management and quality of life for individuals with FXS.
Looking Ahead
We look forward to our continued partnership with Kaerus Bioscience as they move forward with this groundbreaking research. For more information on KER-0193 and Kaerus Bioscience’s work, you can read the full announcement on their website.
.
This is an exciting time for Fragile X research, and we’ll continue to bring you the latest updates as progress unfolds. Stay tuned!
learn more
Visit the RECONNECT MyFXReserach post for more infromation:
Clinical Trial RECONNECT: ZYN002 Gel | MyFXResearch Portal (fragilex.org)
Survey: Developing a Caregiver-Reported Survey in Neurodevelopmental Disorders: The Neurodevelopmental Disorder-Health Index (NDD-HI)
The Center of Health and Technology’s (CheT) Outcomes Division is conducting is conducting a survey to learn about [the most prevalent and impactful symptoms of FXS that the individual experiences, as reported by the caregiver.
Why is the RECONNECT trial with ZYN002 Being Conducted in Fragile X Syndrome?
Zynerba Pharmaceuticals shares why the RECONNECT trial with ZYN002 is being conducted in Fragile X syndrome